Bloomberg News

Siga Shouldn’t Have to Pay PharmAthene Over Drug, Lawyer Says

January 10, 2013

Siga Technologies Inc. (SIGA:US) shouldn’t have to hand over 50 percent of the profits from a smallpox medicine to rival PharmAthene Inc. (PIP:US), lawyers for the drugmaker told an appeals court today.

To contact the reporter on this story: Phil Milford in Wilmington, Delaware at

To contact the editor responsible for this story: Andrew Dunn at

We Almost Lost the Nasdaq

(enter your email)
(enter up to 5 email addresses, separated by commas)

Max 250 characters

Companies Mentioned

  • SIGA
    (SIGA Technologies Inc)
    • $2.65 USD
    • 0.06
    • 2.08%
  • PIP
    (PharmAthene Inc)
    • $1.39 USD
    • -0.02
    • -1.44%
Market data is delayed at least 15 minutes.
blog comments powered by Disqus